Parenteral Antibiotics Market
Parenteral Antibiotics Market Forecasts to 2032 – Global Analysis By Drug Class (Penicillins, Macrolides, Cephalosporins, Glycopeptides, Carbapenems, Aminoglycosides, and Other Drug Classes), Spectrum of Activity, Formulation Type, Route of Administration, Indication, End User and By Geography
According to Stratistics MRC, the Global Parenteral Antibiotics Market is accounted for $25.74 billion in 2025 and is expected to reach $39.48 billion by 2032 growing at a CAGR of 6.3% during the forecast period. Parenteral antibiotics refer to drugs given outside the digestive system, commonly via intravenous, intramuscular, or subcutaneous injection. They are preferred for urgent treatment, cases where oral intake is not feasible, or when gastrointestinal absorption is inadequate. This method delivers the medication directly into the bloodstream, providing rapid action, greater bioavailability, and effective management of serious or widespread infections requiring immediate intervention.
According to a study published in National Canter for Biotechnology Information (NCBI) in November 2021, in Nepal, the total defined daily dose (DDD) of parenteral antibiotics reached 48,947.7 in 2019 with an increase of 23% from 39,639.7 in 2017.
Market Dynamics:
Driver:
Growing antimicrobial resistance (AMR)
As pathogens evolve and become resistant to conventional treatments, healthcare providers are turning to injectable formulations for faster and more effective outcomes. This trend is especially pronounced in hospital settings where multidrug-resistant infections are prevalent. Technological advancements in drug delivery systems and formulation science are enhancing the efficacy of parenteral antibiotics. The rise of precision medicine and pathogen-specific therapies is further boosting market growth. Global health agencies are also prioritizing AMR mitigation, driving investment in novel antibiotic classes and stewardship programs.
Restraint:
High cost of development and commercialization
Extensive clinical trials, stringent safety protocols, and compliance with global standards like FDA and EMA regulations contribute to prolonged timelines and elevated costs. Incorporating advanced technologies such as liposomal delivery and extended-release mechanisms adds complexity to the approval process. Smaller pharmaceutical firms often face resource constraints, limiting their ability to innovate or scale production. Additionally, the need for cold chain logistics and sterile packaging increases operational expenses. These factors collectively hinder rapid market entry and slow down the pace of therapeutic innovation.
Opportunity:
Growing outpatient parenteral antibiotic therapy (OPAT)
The expansion of outpatient parenteral antibiotic therapy (OPAT) is unlocking new growth avenues for the market. OPAT enables patients to receive intravenous antibiotics outside hospital settings, reducing inpatient burden and healthcare costs. Advances in portable infusion devices and remote monitoring technologies are making OPAT more accessible and safer. Healthcare systems are increasingly adopting decentralized care models, with home-based treatments gaining traction. Reimbursement reforms and clinical guidelines are supporting OPAT integration into mainstream care. This shift is driving demand for user-friendly, stable, and long-acting parenteral antibiotic formulations tailored for outpatient use.
Threat:
Increased competition from generics
Patent expirations and regulatory incentives for biosimilar development are accelerating generic entry. While generics improve accessibility, they also compress profit margins for originator companies. Technological parity in manufacturing and formulation is narrowing the differentiation gap. Emerging markets are witnessing a surge in local generic production, intensifying competitive dynamics. To maintain market share, innovators must invest in lifecycle management strategies, such as reformulations and combination therapies.
Covid-19 Impact:
The COVID-19 pandemic significantly disrupted the parenteral antibiotics landscape, altering demand patterns and supply chain operations. Elective procedures were postponed, reducing hospital-based antibiotic usage, while ICU admissions surged, increasing demand for broad-spectrum injectables. Manufacturing delays and global logistics bottlenecks led to temporary shortages of critical antibiotics. However, the crisis accelerated digital health adoption, including remote prescribing and telemedicine-based OPAT programs. Regulatory bodies introduced emergency pathways to fast-track approvals and ensure drug availability. Post-pandemic recovery is now focused on building resilient supply chains and expanding decentralized treatment models.
The penicillins segment is expected to be the largest during the forecast period
The penicillins segment is expected to account for the largest market share during the forecast period, due to its broad-spectrum efficacy and established clinical utility. These antibiotics are widely used in treating respiratory, skin, and urinary tract infections, especially in inpatient settings. Continuous improvements in formulation stability and dosing convenience are reinforcing their market leadership. The development of extended-spectrum penicillins and beta-lactamase inhibitor combinations is enhancing resistance management. Hospitals favor penicillins for their safety profile and cost-effectiveness, particularly in high-volume treatment scenarios. Emerging trends include dual-drug regimens and integration into OPAT protocols.
The ambulatory surgical centers segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the ambulatory surgical centers segment is predicted to witness the highest growth rate, driven by the rise in outpatient procedures. ASCs are increasingly performing complex surgeries that require perioperative antibiotic prophylaxis. Integration of smart infusion systems and cloud-based inventory tracking is streamlining antibiotic administration. Favorable reimbursement policies and shorter patient stays are boosting ASC utilization. The shift toward minimally invasive techniques is increasing demand for rapid-acting injectable antibiotics. Innovations in compact antibiotic kits and single-dose packaging are tailored for ASC workflows.
Region with largest share:
During the forecast period, the Asia Pacificregion is expected to hold the largest market share, supported by expanding healthcare infrastructure and rising infection rates. Countries like China, India, and Indonesia are investing in hospital capacity and antibiotic manufacturing capabilities. Government initiatives promoting local production and antimicrobial stewardship are fueling market expansion. The region is witnessing rapid adoption of injectable therapies in both urban and rural settings. Strategic collaborations between global pharmaceutical firms and regional players are enhancing distribution and technology transfer. Emerging trends include AI-assisted diagnostics and mobile OPAT units in underserved areas.
Region with highest CAGR:
Over the forecast period, the North Americaregion is anticipated to exhibit the highest CAGR, driven by technological innovation and robust healthcare spending. The U.S. and Canada are leading in the development of novel parenteral antibiotic formulations, including liposomal and nanoparticle-based injectables. Regulatory agencies are streamlining approval pathways for critical antibiotics, encouraging faster market entry. Hospitals are integrating electronic prescribing and smart infusion pumps to optimize antibiotic delivery. The region benefits from strong reimbursement frameworks and high awareness of AMR challenges. As personalized medicine and outpatient care expand, North America remains at the forefront of antibiotic innovation.
Key players in the market
Some of the key players in Parenteral Antibiotics Market include Pfizer Inc., Sandoz, Merck & Co., Inc., Spero Therapeutics, Johnson & Johnson, AstellasPharma Inc., GlaxoSmithKline plc, Entasis Therapeutics, Sanofi, F. Hoffmann-La Roche Ltd, Novartis AG, Bristol-Myers Squibb, Bayer AG, Eli Lilly and Company, and Abbott Laboratories.
Key Developments:
In September2025, Pfizer Inc. and Metsera, Inc. announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. The acquisition brings deep expertise and a portfolio of differentiated oral and injectable incretin, non-incretin and combination therapy candidates with potential best-in-class efficacy and safety profiles.
In February2025, Shedd Aquarium and global healthcare company Abbott are announcing one of Shedd’s largest corporate gifts in recent history a $10 million pledge from Abbott and Abbott's philanthropic foundation, Abbott Fund. The investment cements the longstanding partnership between Shedd, Abbott, and Abbott Fund to enrich the cultural, educational and environmental fabric of Chicago and spark passion for protecting the ocean environment.
Drug Classes Covered:
• Penicillins
• Macrolides
• Cephalosporins
• Glycopeptides
• Carbapenems
• Aminoglycosides
• Other Drug Classes
Spectrum of Activities Covered:
• Broad-Spectrum Antibiotics
• Narrow-Spectrum Antibiotics
Formulation Types Covered:
• Single-Dose Vials
• Multi-Dose Vials
• Infusion Bags
• Pre-filled Syringes
Route of Administrations Covered:
• Intravenous (IV)
• Subcutaneous (SC)
• Intramuscular (IM)
Indications Covered:
• Respiratory Infections
• Urinary Tract Infections
• Skin and Soft Tissue Infections
• Hospital-Acquired Infections
• Intra-abdominal Infections
• Surgical Site Infections
• Sepsis and Bloodstream Infections
• Other Applications
End Users Covered:
• Hospitals
• Home Healthcare
• Specialty Clinics
• Ambulatory Surgical Centers
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Parenteral Antibiotics Market, By Drug Class
5.1 Introduction
5.2 Penicillins
5.3 Macrolides
5.4 Cephalosporins
5.5 Glycopeptides
5.6 Carbapenems
5.7 Aminoglycosides
5.8 Other Drug Classes
6 Global Parenteral Antibiotics Market, By Spectrum of Activity
6.1 Introduction
6.2 Broad-Spectrum Antibiotics
6.3 Narrow-Spectrum Antibiotics
7 Global Parenteral Antibiotics Market, By Formulation Type
7.1 Introduction
7.2 Single-Dose Vials
7.3 Multi-Dose Vials
7.4 Infusion Bags
7.5 Pre-filled Syringes
8 Global Parenteral Antibiotics Market, By Route of Administration
8.1 Introduction
8.2 Intravenous (IV)
8.3 Subcutaneous (SC)
8.4 Intramuscular (IM)
9 Global Parenteral Antibiotics Market, By Indication
9.1 Introduction
9.2 Respiratory Infections
9.3 Urinary Tract Infections
9.4 Skin and Soft Tissue Infections
9.5 Hospital-Acquired Infections
9.6 Intra-abdominal Infections
9.7 Surgical Site Infections
9.8 Sepsis and Bloodstream Infections
9.9 Other Applications
10 Global Parenteral Antibiotics Market, By End User
10.1 Introduction
10.2 Hospitals
10.3 Home Healthcare
10.4 Specialty Clinics
10.5 Ambulatory Surgical Centers
10.6 Other End Users
11 Global Parenteral Antibiotics Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 New Zealand
11.4.6 South Korea
11.4.7 Rest of Asia Pacific
11.5 South America
11.5.1 Argentina
11.5.2 Brazil
11.5.3 Chile
11.5.4 Rest of South America
11.6 Middle East & Africa
11.6.1 Saudi Arabia
11.6.2 UAE
11.6.3 Qatar
11.6.4 South Africa
11.6.5 Rest of Middle East & Africa
12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies
13 Company Profiling
13.1 Pfizer Inc.
13.2 Sandoz
13.3 Merck & Co., Inc.
13.4 Spero Therapeutics
13.5 Johnson & Johnson
13.6 Astellas Pharma Inc.
13.7 GlaxoSmithKline plc
13.8 Entasis Therapeutics
13.9 Sanofi
13.10 F. Hoffmann-La Roche Ltd
13.11 Novartis AG
13.12 Bristol-Myers Squibb
13.13 Bayer AG
13.14 Eli Lilly and Company
13.15 Abbott Laboratories
List of Tables
1 Global Parenteral Antibiotics Market Outlook, By Region (2024-2032) ($MN)
2 Global Parenteral Antibiotics Market Outlook, By Drug Class (2024-2032) ($MN)
3 Global Parenteral Antibiotics Market Outlook, By Penicillins (2024-2032) ($MN)
4 Global Parenteral Antibiotics Market Outlook, By Macrolides (2024-2032) ($MN)
5 Global Parenteral Antibiotics Market Outlook, By Cephalosporins (2024-2032) ($MN)
6 Global Parenteral Antibiotics Market Outlook, By Glycopeptides (2024-2032) ($MN)
7 Global Parenteral Antibiotics Market Outlook, By Carbapenems (2024-2032) ($MN)
8 Global Parenteral Antibiotics Market Outlook, By Aminoglycosides (2024-2032) ($MN)
9 Global Parenteral Antibiotics Market Outlook, By Other Drug Classes (2024-2032) ($MN)
10 Global Parenteral Antibiotics Market Outlook, By Spectrum of Activity (2024-2032) ($MN)
11 Global Parenteral Antibiotics Market Outlook, By Broad-Spectrum Antibiotics (2024-2032) ($MN)
12 Global Parenteral Antibiotics Market Outlook, By Narrow-Spectrum Antibiotics (2024-2032) ($MN)
13 Global Parenteral Antibiotics Market Outlook, By Formulation Type (2024-2032) ($MN)
14 Global Parenteral Antibiotics Market Outlook, By Single-Dose Vials (2024-2032) ($MN)
15 Global Parenteral Antibiotics Market Outlook, By Multi-Dose Vials (2024-2032) ($MN)
16 Global Parenteral Antibiotics Market Outlook, By Infusion Bags (2024-2032) ($MN)
17 Global Parenteral Antibiotics Market Outlook, By Pre-filled Syringes (2024-2032) ($MN)
18 Global Parenteral Antibiotics Market Outlook, By Route of Administration (2024-2032) ($MN)
19 Global Parenteral Antibiotics Market Outlook, By Intravenous (IV) (2024-2032) ($MN)
20 Global Parenteral Antibiotics Market Outlook, By Subcutaneous (SC) (2024-2032) ($MN)
21 Global Parenteral Antibiotics Market Outlook, By Intramuscular (IM) (2024-2032) ($MN)
22 Global Parenteral Antibiotics Market Outlook, By Indication (2024-2032) ($MN)
23 Global Parenteral Antibiotics Market Outlook, By Respiratory Infections (2024-2032) ($MN)
24 Global Parenteral Antibiotics Market Outlook, By Urinary Tract Infections (2024-2032) ($MN)
25 Global Parenteral Antibiotics Market Outlook, By Skin and Soft Tissue Infections (2024-2032) ($MN)
26 Global Parenteral Antibiotics Market Outlook, By Hospital-Acquired Infections (2024-2032) ($MN)
27 Global Parenteral Antibiotics Market Outlook, By Intra-abdominal Infections (2024-2032) ($MN)
28 Global Parenteral Antibiotics Market Outlook, By Surgical Site Infections (2024-2032) ($MN)
29 Global Parenteral Antibiotics Market Outlook, By Sepsis and Bloodstream Infections (2024-2032) ($MN)
30 Global Parenteral Antibiotics Market Outlook, By Other Applications (2024-2032) ($MN)
31 Global Parenteral Antibiotics Market Outlook, By End User (2024-2032) ($MN)
32 Global Parenteral Antibiotics Market Outlook, By Hospitals (2024-2032) ($MN)
33 Global Parenteral Antibiotics Market Outlook, By Home Healthcare (2024-2032) ($MN)
34 Global Parenteral Antibiotics Market Outlook, By Specialty Clinics (2024-2032) ($MN)
35 Global Parenteral Antibiotics Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
36 Global Parenteral Antibiotics Market Outlook, By Other End Users (2024-2032) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We offer complimentary customization of up to 15% with every purchase. To share your customization requirements, feel free to email us at info@strategymrc.com or call us on +1-301-202-5929. .
Please Note: Customization within the 15% threshold is entirely free of charge. If your request exceeds this limit, we will conduct a feasibility assessment. Following that, a detailed quote and timeline will be provided.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
